This module uses fundamental data of NLS Pharmaceutics to approximate its Piotroski F score. NLS Pharmaceutics F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of NLS Pharmaceutics AG. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about NLS Pharmaceutics financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Check out NLS Pharmaceutics Altman Z Score, NLS Pharmaceutics Correlation, NLS Pharmaceutics Valuation, as well as analyze NLS Pharmaceutics Alpha and Beta and NLS Pharmaceutics Hype Analysis.
NLS
Piotroski F Score
Market Cap
Enterprise Value
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Average Payables
Pb Ratio
Free Cash Flow Per Share
Roic
Net Income Per Share
Cash Per Share
Pocfratio
Interest Coverage
Pfcf Ratio
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Graham Number
Shareholders Equity Per Share
Debt To Equity
Graham Net Net
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Ebt Per Ebit
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Quick Ratio
Cash Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Return On Assets
Price Fair Value
Return On Equity
Change To Inventory
Change In Cash
Net Borrowings
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Cashflows From Financing Activities
Other Non Cash Items
Total Cash From Operating Activities
Change To Account Receivables
Change To Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Change To Netincome
Change To Liabilities
Depreciation
Total Assets
Short Long Term Debt Total
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Other Liab
Net Tangible Assets
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Other Assets
Long Term Debt
Cash And Short Term Investments
Net Receivables
Common Stock Total Equity
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Non Current Liabilities Total
Other Current Assets
Other Stockholder Equity
Total Liab
Net Invested Capital
Total Current Assets
Accumulated Other Comprehensive Income
Net Working Capital
Common Stock
Inventory
Short Long Term Debt
Capital Stock
Short Term Debt
Property Plant And Equipment Net
Net Interest Income
Depreciation And Amortization
Interest Expense
Selling General Administrative
Other Operating Expenses
Operating Income
Net Income From Continuing Ops
Ebit
Research Development
Ebitda
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Net Income Applicable To Common Shares
Income Tax Expense
Selling And Marketing Expenses
Reconciled Depreciation
Probability Of Bankruptcy
As of 11/27/2024, Net Debt is likely to grow to about 772.9 K, while Short and Long Term Debt Total is likely to drop slightly above 1.4 M. At this time, NLS Pharmaceutics' ROIC is relatively stable compared to the past year. As of 11/27/2024, ROE is likely to grow to 1.45, while Free Cash Flow Yield is likely to drop (0.01).
At this time, it appears that NLS Pharmaceutics' Piotroski F Score is Unavailable. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
The critical factor to consider when applying the Piotroski F Score to NLS Pharmaceutics is to make sure NLS is not a subject of accounting manipulations and runs a healthy internal audit department. So, if NLS Pharmaceutics' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if NLS Pharmaceutics' financial numbers are properly reported.
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between NLS Pharmaceutics' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards NLS Pharmaceutics in a much-optimized way.
F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.
Book Value Per Share
(0.24)
At this time, NLS Pharmaceutics' Book Value Per Share is relatively stable compared to the past year.
NLS Pharmaceutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of NLS Pharmaceutics from analyzing NLS Pharmaceutics' financial statements. These drivers represent accounts that assess NLS Pharmaceutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of NLS Pharmaceutics' important valuation drivers and their relationship over time.
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, NLS Pharmaceutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to NLS Pharmaceutics' managers, analysts, and investors.
Environmental
Governance
Social
About NLS Pharmaceutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze NLS Pharmaceutics AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NLS Pharmaceutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NLS Pharmaceutics AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if NLS Pharmaceutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NLS Pharmaceutics will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to NLS Pharmaceutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace NLS Pharmaceutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back NLS Pharmaceutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling NLS Pharmaceutics AG to buy it.
The correlation of NLS Pharmaceutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as NLS Pharmaceutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if NLS Pharmaceutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for NLS Pharmaceutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
When running NLS Pharmaceutics' price analysis, check to measure NLS Pharmaceutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NLS Pharmaceutics is operating at the current time. Most of NLS Pharmaceutics' value examination focuses on studying past and present price action to predict the probability of NLS Pharmaceutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NLS Pharmaceutics' price. Additionally, you may evaluate how the addition of NLS Pharmaceutics to your portfolios can decrease your overall portfolio volatility.